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Five different musearlnie receptor subtypes ean be distinguished by the differenees in their amino aeid sequence, 
the eoupled signal transduetion system, pharmaeologieal binding properties and aetivation of ionie fluxes. The present 
study served to eharaeterize the binding profile of musearlnie receptors in human eolon eareinoma eells (HT-29) using 
seleetive musearlnie antagonists. The affinities of the compounds were eompared with their poteney to inhibit 
cholinergieally-aetivated phosphoinositide metabolism. Pirenzepine displaeed eHJN-methyl-scopolamine binding and 
inhibited inositolphosphate (IP) release with potencies typieal of those of non-M1 receptors. The M3 subtype-selective 
antagonists sila-hexocyelium and hexahydro-sila-difenidol bad high affinity to the musearlnie reeeptors in HT-29 cells 
(K 0 = 3.1 nM and 27 nM, respectively) and inhibited IP release at nanomolar concentrations. The M2 reeeptor 
antagonists, AF-DX 116 and methoctramine, had low antimusearinic poteneies. Our results demonstrate that HT-29 
human colon earcinoma cells contain an apparently pure population of M3 receptors. These cells could serve as a 
model system for further investigations coneerning regulatory and signal transduction mechanisms associated with 
glandular musearinic M 3 receptors. 
Muscarinic M3 receptor subtypes; HT-29 eolon earcinoma cells; Phosphatidylinositol metabolism; AF-DX 116; 
Sila-hexocyelium; Hexhydro~sila-difenidol; Methoctramine 
Introduction 
The activation of musearlnie acetylcholine re-
ceptors (mAChR) in a wide variety of tissues 
induces hydrolysis of polyphosphoinositides and 
subsequently increases the release of the second 
messengers, inositoltrisphosphate (IP3 ) and di-
acylglycerol (DAG) (Nathanson, 1987). This re-
sults in mobilization of intracellular calcium stores 
and activation of the calcium-sensitive, phos-
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pholipid-dependent protein kinase C family 
(Berridge, 1987; Nishizuka, 1986). 
The development of antagonists which have 
different affinities for subtypes of muscarinic re-
ceptors permitted their pharmacological classifica-
tion. The M1-selective antagonist, pirenzepine, al-
lowed M1 and M2/M 3 receptors (terminology 
used according to Bonner et al., 1988) to be dif-
ferentiated based on a higher affinity to M1 recep-
tors (Hammer et al., 1980). Furthermore, the dis-
covery of selective antagonists permitted a distinc-
tion between cardiac (M 2 ; previously termed M 2 a 
by us) and glandular or smooth muscle-typical 
(M 3; previously termed M2p by us) receptor sub-
types. Antagonists such as sila-hexocyclium (SiHC) 
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and hexahydro-sila-difenidol (HHSiD) bound 
potently to glandular M3 receptors at nanomolar 
concentrations, while methoctramine or AF-DX 
116 showed higher affinities for cardiac M 2 recep-
tors (Mutschler and Lambrecht, 1984; Lambrecht 
and Mutschler, 1985; Giachetti et al., 1986; 
Hammer et al., 1986; Melchiorre et al., 1987; 
Lambrecht et al., 1988; Waelbroeek et al., in press). 
The existenee of at least five musearlnie recep-
tor subtypes has now been confirmed in molecular 
terms (Kubo et al., 1986a,b; Bonner et al., 1987; 
Peraha et al., 1987a,b). Experiments on expression 
of cloned receptors in neuroblastoma eells and 
CHO-K1 cells proved the aetivity of these recep-
tors and showed their speeifie eoupling to differ-
ent second messenger systems and ionie currents 
(Fukuda et al., 1988; Peralta et al., 1988). Al-
though the terminology for the different receptor 
subtypes is still confusing, binding sturlies indieate 
that musearlnie receptors with low affinities for 
pirenzepine are best represented by the M 3 recep-
tor subtype. These receptors bind HHSiD and 
SiHC with high affinity and are eoupled to the 
phosphoinositide system. This reeeptor subtype is 
identical with the mAChRIII or M4 reeeptor sub-
type, as deseribed by Fukuda et al. (1988) and 
Peralta et al. (1988), respectively (for overview see 
Bamard, 1988). 
We reeently reported that glandular non-M1 
musearlnie reeeptors of rat parietal eells mediate 
eholinergieally stimulated aeid secretion by aetiva-
tion of the phosphoinositide system (Pfeiffer et al., 
1988). Current investigations indieate that this 
hydrogen ion produetion is mediated by M 3 
reeeptors (Pfeiffer et al., submitted). Additionally, 
we reported that musearinie M 3 reeeptors in 
porcine gastrie mueosa also showed nanomolar 
affinities for HHSiD and differed significantly 
from musearlnie subtypes in gastrie muscularis 
(Herawi et al., 1988). 
The aim of the present study was to ehar-
aeterize the musearlnie reeeptor subtype, in a hu-
man eolon eareinoma eell line HT -29, found to 
potently aetivate the phoshoinositide system in 
response to eholinergie Stimulation (Kopp et al., 
1988). We therefore eompared the binding proper-
lies of N -methyl-seopolamine (NMS), earbaehol, 
pirenzepine and atropine to HT-29 eells to their 
poteney to stimulate the release of inositol phos-
phates. To eharaeterize the musearinic reeeptor 
subtype involved, we determined the binding pro-
file of the subtype-seleetive antagonists HHSiD, 
SiHC, AF-DX 116 and methoetramine and their 
inhibitory poteney on inositol phosphate release. 
The results indieated that musearlnie reeeptors 
coupled to the phosphoinositide system in HT -29 
eells are most likely of the M 3 receptor sub type. 
Thus, HT-29 eells may be used as a weil defined 
model system for further investigations of reeeptor 
regulation and signal transduetion meehanisms of 
human intestinal musearinie reeeptors. The lower 
affinity of HHSiD we now observed, eompared to 
previous results obtained in rat parietal eells and 
poreine gastrie mueosa, suggests the existenee of 
speeies-related heterogeneity in musearlnie recep-
tor subtypes. 
2. Materials and methods 
2.1. Ce/1 culture 
Cells were obtained from the Ameriean Type 
Culture Colleetion (A TCC, Rockville, MD, 
U.S.A.), subeultured with 0.05% trypsin/1 mM 
EDTA in Dulbeeco's modified Eagle's medium 
(DMEM), eontaining 6% fetal ealf serum (FCS), 1 
mM pyruvie aeid, 2 mM glutamine, 100 U jml 
penieillin, 50 U /ml Streptomycin and 200 I.U./ml 
nystatin in 75 em2 disposable tissue eulture flasks 
in a humified atmosphere of 5% C02 j95% air. For 
the experiments, eells were seeded at a density of 
2 X 105 eells in 24-well flat bottarn tissue eulture 
plates (Falcon, Heidelberg, F.R.G.) and grown as 
monolayers until subeonflueney (0.7-LO X 106 
eellsjwell). 
2.2. Determination of [ 3Hjinositol phosphates 
For measurements of inositol phosphate re-
lease, eells were preincubated with [3H]myo-in-
ositol (2 pCijml) for 48 h when eomplete isotopic 
equilibrium was achieved. Aeeumulation of in-
ositol phosphateswas measured in the presence of 
LiCI (10 mM}, known to inhibit the degradation 
of inositol monophosphates (Berridge et al., 1982). 
The cells were then stimulated for 30 min with 
carbachol (0.1 mM). Phospholipase C activity, as 
represented by inositol phosphate release, was 
determined as described by Pfeiffer et al. (1988), 
using the Dowex anion exchange technique 
(Downes and Michell, 1981). Inositol phosphates 
were eluted with 1 M ammonium formatejO.l M 
formic acid. Antimuscarinic compounds were 
added to the incubation medium 45 min prior to 
stimulation with carbachol to allow complete equi-
librium to be reached. The pA 2 values for 
pirenzepine were obtained from dose-response 
curves repeated in the presence of various con-
centrations of pirenzepine and the dose ratios at 
I C50 values were determined ( Arunlakshana and 
Schild, 1959). 
2. 3. Binding studies 
The cells were incubated in the presence of 0.25 
nM [ 3H]NMS (specific activity 72 Cijmmol) for 
60 min in Hanks' balanced salts solution (HBSS), 
containing HEPES 20 mM, NaHC03 3.7 gjl, 
glutamine 2 mM, pyruvic acid 2 mM, at room 
temperature. The cells were then washed rapidly 
with ice-cold HBSS, dissolved in 0.5 M N aOH 
and radioactivity was measured by liquid scintilla-
tion spectrophotometry. Specific binding was 
calculated after subtraction of non-specific bind-
ing in the presence of 1 p.M atropine. Specific 
receptor binding was 82 ± 5% of the total bound 
radioacti vi ty. 
2. 4. Data analysis 
The data are reported as means ± S.E.M. from 
three or more independent experiments, each per-
formed in triplicate. The data were analyzed with 
the computerized non-linear Ieast-squares regres-
sionprogram (LIGAND and ALLFIT (De Lean 
et al., 1978; Munson and Rodbard, 1980). 
2. 5. Drugs and radiochemieals 
All reagents were of analytical grade and 
purchased from Merck, Darmstadt, F.R.G., unless 
indicated otherwise. HEPES was from Serva 
(Heidelberg, F.R.G.), DMEM, HBSS and FCS 
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were from Gibco (Karlsruhe, F.R.G.) and 
[ 3 H]NMS, eH]myo-inositol from Amersham 
Buchler, (Dreieich, F.R.G.). Pirenzepine dihydro-
chloride was kindly supplied by Dr. Hammer, 
Boehringer (lngelheim, F.R.G.) and methoctra-
mine tetrahydrochloride by Dr. Melchiorre, Uni-
versity of Bologna. HHSiD and SiHC were 
synthesized as described (Tacke et al., 1985, 1989). 
AF-DX 116 was a kind gift from Dr. A. Zimmer 
and Dr. G. Trummlitz, Dr. Karl Thomae GmbH, 
Biberach, F.R.G. Unlabeled NMS and carbachol 
were from Sigma (Taufkirchen, F.R.G.). 
3. Results 
3.1. Binding affinities of muscarinic antagonists 
The binding profiles of muscarinic receptors on 
HT-29 cells were investigated in binding assays 
with tritiated NMS and various selective 
muscarinic antagonists. [ 3 H]NMS labeled a single 
population of muscarinic receptors on HT -29 cells 
with an affinity of 0.15 nM (K 0 ). The receptor 
capacitywas 5.35 fmolj10 6 cells, corresponding to 
3300 binding sites per single cell. Atropine dis-
placed [ 3 H]NMS in a dose-dependent fashion with 
a K 0 of 0.79 nM. The M1-selective antagonist, 
pirenzepine, competed with [3 H]NMS for a single 
binding site with a low affinity of 279 nM (n = 3), 
indicating the presence of M2 or M 3 muscarinic 
receptors in HT-29 cells (fig. 1 and table 1). The 
agonist carbachol bound to a single binding si te 
with an affinity of 15 ~tM (table 1). 
To further investigate the muscarinic receptor 
subtypes present in HT -29 cells, we characterized 
the binding profile of the subtype selective 
antagonists HHSiD, SiHC and AF-DX 116. 
HHSiD, SiHC and AF-DX 116 completely dis-
placed tritiated NMS from a single binding site 
with affinities of 27 ± 4.5 nM for HHSiD (n = 5), 
3.1 ± 0.6 nM for SiHC (n = 3) and 7564 ± 879 nM 
for AF-Dx 116 (n = 5, fig. 2). The binding data 
for the three antagonists did not permit better fits 
to two-site models. 
Although the relatively low binding affinity of 
AF-DX 116 did not suggest the presence of M 2 
receptors in HT-29 cells, we also investigated the 
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Fig. 1. Displacement of [3 H]NMS (0.25 nM) by unlabeled 
NMS, atropine and pirenzepine. Curves represent one-site fits 
analyzed with the LIGAND program. The data· points are 
from three independent experiments for each compound, per-
formed in triplicate. 
binding profile of the highly M 2 selective 
antagonist, methoctramine (Melchiorre et al., 
1987). As expected, methoctramine displaced 90% 
of [3H]NMS binding from a single binding site 
with an extremely low binding affinity (K 0 : 2022 
± 262 nM, n = 3) (fig. 3). This permitted us to 
exclude the possible existence of even a small 
population of M2 binding sites. Attempts to 
analyze the displacement curve of methoctramine 
TABLEI 
Affinity of musearlnie antagonists for ( 3 H]N-methyl-scopola-
mine (NMS) binding sites in comparison to their inhibitory 
potencies on 0.1 mM carbachol-stimulated inositol phosphate 
release in HT-29 cells. Each number represents the result from 
3-5 experiments, each performed in triplicate. The binding data 
were analyzed with the LIGAND program, while the IC50 
values of inositol phosphate accumulation were calculated with 
the ALLFIT program. N.D. =not determined. 
Ligand [ 3 H]NMS binding ICso values of 
(K 0 , nM) inositol phos-
phate accumu-
lation (nM} 
NMS 0.15± 0.03 N.D. 
Atropine 0.79± 0.07 11.22± 1.61 
Pirenzepine 279 ± 34 1836 ±159 
Carbachol 15100 ±2100 
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Fig. 2. Displacement of [ 3 H]NMS by the musearlnie M 3 
(M 2.B)-selective antagonists, SiHC and HHSiD, and by the 
cardioselective (M 2) antagonist, AF-DX 116. The data points 
are means of three independent experiments for each cam-
peund and were analyzed with the LIGAND program. The 
values for specifically bound radioactivity correspond to 320 ± 
39 cpm/106 cells. 
using a model of two binding sites did not reveal a 
significant increase in the 'goodness of fit'. 
3.2. lnhibitory effects of muscarinic antagonists on 
carbachol-stimulated inositolphosphate release 
To assess the second messenger system in-
volved in the signal transduction activated by 
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Fig. 3. Displacement of [3H]NMS by the M 2 (M 2a)-selective 
antagonist methoctramine. The curve corresponds to data of 
three independent experimentsandwas fitted by means of the 
LIGAND program. Specifically bound radioactivity was 389 ± 
46 cpm/106 cells. 
musearlnie receptors we investigated the cholin-
ergic activation of the phosphoinositide system by 
determination of inositol phosphate release in the 
presence of LiCl (10 mM). The carbachol-stimu-
lated inositol phosphate release (30 min, 0.1 mM) 
was inhibited dose dependently by atropine and 
pirenzepine with IC50 values of 11.2 and 1836 nM 
(n = 3), respectively (table 1). Since the inhibitory 
effects of antagonists are dependent on the 
concentrations of agonist used for stimulation of 
phosphoinositide metabolism, the IC50 values ex-
ceeded the K 0 values, due to a parallel shift to the 
right of the dose-response curves. Schild analysis 
was performed to obtain a more precise estimate 
of the affinity of pirenzepine to muscarinic recep-
tors mediating the increase in inositol phosphates. 
The dose-response relationships for stimulation of 
IP release are shown in fig. 4A. lncreasing 
concentrations of pirenzepine caused parallel shifts 
in the dose-response curves for carbachol, typical 
for competitive antagonism. Arunlakshana and 
Schild analysis (1959) indicated a pA 2 value of 
6.73. The slope of the Schild plot (0.95 ± 0.03, fig. 
4B) was not significantly different from unity (P 
> 0.05). 
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Fig. 5. Dose·response curve for the inhibition of carbachol· 
activated (30 min, 0.1 mM) inositol phosphate release by 
HHSiD and AF-DX 116. The data points represent means 
from three independent experiments for each compound. The 
basal and stimulated values for inositol phosphate release 
correspond to 172 ± 26 and 818 ± 87/106 cells, respectively. 
The curves were analyzed with the ALLFIT program. 
To investigate whether the cholinergic activa-
tion of phosphoinositide metabolism is mediated 
by the above described receptor subtype in HT-29 
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Fig. 4. Dose-response curves for the Stimulation of inositol phosphate release by carbachol (30 min, 0.1 mM) either alone, or in the 
presence of indicated concentrations of pirenzepine (A) and Schildplot (B) from the data shown in (A). The basal and stimulated 
values for inositol phosphate accumulation were 142 ± 8 and 466 ± 22 cpm/106 cells, respectively. The curves were fitted with the 
ALLFIT program. The Schild p1ot was calculated according to Arunlakshana and Schild (1959). 
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cells, we determined the inhibitory effects of 
hexahydro-sila-difenidol and AF-DX 116 on 
carbachol-stimulated inositol phosphate release. 
Incubations with HHSiD and AF-DX 116 alone 
did not inerease inositolphosphate aeeumulation, 
excluding the possibility of partial agonism for 
these compounds. As shown in fig. 5, both 
antagonists dose dependently reduced carbaehol-
stimulated inositol phosphate release with half-
maximal concentrations of 270 ± 52 nM for 
HHSiD and 9200 ± 180 nM (n = 3) for AF-DX 
116. These results show clearly that musearlnie M 3 
reeeptor subtypes mediate the stimulation of phos-
phoinositide metabolism in HT-29 cells. 
4. Discussion 
Human HT -29 colon carcinoma eells have been 
deseribed to contain binding sites for various 
hormones and peptides including insulin (Forgue-
Lafitte et al., 1979), epidermal growth factor 
(Kitabgi et al., 1979), vasoaetive intestinal poly-
peptide (Laburthe et al., 1978) and neurotensin 
(Kitabgi et al., 1980) and the a 2-adrenoceptor 
(Bousearel et al., 1985). Ineubation of HT-29 eells 
with neurotensin has been shown to result in 
aetivation of the phosphoinositide system (Amar 
et al., 1986). 
The data we now obtained indicate that the 
HT-29 cellline eontains an apparently pure popu-
lation of musearlnie receptors of the glandular M 3 
subtype and demoostrate their coupling to the 
phosphoinositide second messenger system. In-
cubations with the M1-seleetive antagonist, 
pirenzepine, revealed a more than 100-fold lower 
binding affinity as compared to atropine, typical 
for the presence of M2 or M3 receptors in HT-29 
eells (table 1). The low affinities of AF-DX 116 
and methoctramine allowed us to exclude the 
presence of M2 receptor subtypes, while the high-
affinity binding of SiHC and HHSiD ehar-
aeterized the musearlnie receptor in HT-29 eells as 
an M3 subtype (figs. 1-3). The low affinity of 
carbaehol in HT-29 cells is in agreement with 
previous results obtained with poreine gastrie 
mueosa (Herawi et al., 1988). 
It is interesting that the binding affinity of the 
M3-selective antagonist hexahydrosila-difenidol to 
HT-29 eells was about 5-10-fold lower than the 
K 0 values reported for rat gastrie eells (Pfeiffer et 
al., 1988) or porcine gastric cells (Herawi et al., 
1988). These results could indicate that there is 
species-speeifie heterogeneity related to dif-
ferenees in the primary structure, differences in 
receptor-associated G proteins or in the mieroen-
vironment. The high affinity of SiHC, however, 
eonfirmed the presence of M3 receptors in HT-29 
eells. 
The suggestion of a speeies-dependent hetero-
geneity of human musearlnie receptor subtypes is 
supported by results from our laboratory for the 
binding profiles of human gastric mucosa. In these 
experiments HHSiD also displaeed [3H]NMS with 
an affinity approximately 10-20 fold lower than in 
control experiments using porcine gastric mucosa 
(Pfeiffer et al., submitted for publication). Ad-
ditionally, Baudiere et al. (1987) eharacterized the 
musearlnie binding profile for HHSiD in rabbit 
gastric fundie cells and concluded from the K 0 
values around 200 nM that the musearlnie reeep· 
tor subtype mediating acid seeretion may be dif-
ferent from the glandular subtype. Although the 
different binding profiles for musearlnie anta-
gonists may result from species heterogeneity of 
musearinic receptors, the authors did not investi-
gate the binding · profile of a second M3-selective 
antagonistsuch as SiHC. 
Several sturlies investigating musearlnie reeep-
tor subtypes in freshly isolated intestinal smooth 
muscle preparations (Giraldo et al., 1987; Michel 
and Whiting, 1988) evideneed a heterogenous 
population of M2 and M3 reeeptors, as identified 
by different binding affinities for methoctramine. 
This heterogeneity of musearlnie receptors in 
smooth muscle has recently been eonfirmed by 
tissue distribution sturlies of mRNAs encoding 
M2 and M3 reeeptors (Maeda et al., 1989). At-
tempts to correlate receptor subtypes to smooth 
muscle eontraetion indieate that M3 receptors 
mediate this physiologieal response, while the 
funetion of M2 receptors is unknown. Sinee heter-
ogenous populations of musearinie receptors are 
undesirable for investigations on receptor specifie 
phenomena, the remarkably pure population of 
M 3 receptors in HT-29 eells may serve as an 
important model system. 
Binding profiles have now been reported for 
pirenzepine, HHSiD, SiHC, AF-DX 116 and 
methoctramine at eloned musearlnie receptor sub-
types (McM5 ) (Akiba et al., 1988; Buekley et al., 
1989). Comparison of the binding values obtained 
from these studies with our results indieates that 
the receptor present on HT-29 eells is best repre-
sented by the M3 receptor subtype. 
Bonner et al. (1988) demonstrated the existenee 
of a new musearlnie receptor subtype in neuronal 
tissue, designated M 5 , whieh seems tobe eoupled 
to the phosphoinositide system as also postulated 
for the M 3 sub type. The receptor subtype de-
seribed in this study seems unlikely to resemble 
the neuronal M 5 receptor since methoctramine 
has a relatively high affinity in cells transfected 
with the M5 subtype (Buekley et al., 1989). This is 
in contrast to our results, where methoctramine 
behaved as a low-affinity antagonist. 
As mentioned above, the concentrations of at-
ropine, pirenzepine and HHSiD required to obtain 
half-maximal inhibitory effects on stimulated IP-
release exceeded K 0 values about 10-fold. The 
eoneentrations of AF-DX 116 necessary to inhibit 
carbaehol-mediated IP aecumulation were within 
the range of the K 0 value for this eompound, 
suggesting additional effects of AF-DX 116 on M 3 
musearlnie receptor interaction. The most likely 
explanation is a positive allosterie effeet occurring 
with several M 2 antagonists, including AF-DX 
116, as reported by Roffel et al. (1989). 
In summary, the musearlnie binding profile of 
HT-29 cells, as now described, indieates a rela-
tively pure population of M3 (previously termed 
M2p) reeeptors in this eellline, whieh may be used 
as a weil defined model system to investigate the 
regulation of M 3 receptors and the details of the 
receptor coupling system. Kunysz et al. (1989) 
have very reeently provided evidenee for the ex-
istenee of non-cardiae and non-M1 musearlnie 
receptors in a human astrocytoma eell line (1321 
N1 ), which are also linked to phosphoinositide 
turnover and are likely to be of the M 3 receptor 
type. 
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